Three oral and 12 poster presentations demonstrate breadth and progress of AskBio’s gene therapy research and development activities, as well as advancements in manufacturing capabilities AskBio Inc.

Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...

All poster presentations will take place in Poster Hall I2 ... BaseCamp is also establishing a comprehensive approach integrating robust process design, clinical insights, and risk-based analysis, ...

This “trial-in-progress” presentation will focus on the design of the ongoing expansion portion of Mersana’s Phase 1 clinical trial of Emi-Le that is actively enrolling patients with triple ...

today announced the publication of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. In addition to a trial-in-progress study design ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor. Majority of physicians and chronic neutropenia participant ...

The 20th annual John Heinrichs Scholarly and Creative Activity Days (SACAD) was held on April 24. Despite an early threat of ...

The Symposium of Student Research and Creative Activity was a daylong event for motivated students on April 24 to showcase research projects to guests, staff and other students through a poster-board ...